Targeted therapies, which include monoclonal antibodies and small-molecules, have significantly changed the treatment of cancer over the past 10 years. Although traditional cytotoxic chemotherapy is still the widely applied treatment for different types of cancer, targeted therapies are now an important component of treatment for many common malignancies. Targeted therapy has raised new questions about the tailoring of cancer treatment to an individual patient's tumor, the assessment of drug effectiveness and toxicity, and the economics of cancer care.

The meeting will cover the most exciting and promising advances in targeted therapies. The event is designed to promote interactions between young researchers (PhD students and postdoctoral fellows) and leaders in different fields of cancer research to discuss challenges and opportunities in this area.

PLENARY SESSION TOPICS:
- Epigenetics
- Targeting Oncogenic and Tumour Suppressor Transcription Factors: MYC and p53
- Biologics for Cancer Therapies
- Tyrosine Kinase Signal Transduction Pathways

KEYNOTE SPEAKERS:
- Gerard Evan (Cambridge University, UK)
- Mien-Chie Hung (MD Anderson Cancer Center, USA)
- Brian Huntly (Cambridge University, UK)
- David Lane (A*STAR Biomedical Science Institutes, Singapore)
- Greg Winter (Medical Research Council, Cambridge, UK)

APPLICATION DEADLINE: April 30, 2013
Please send to act@mtc.ki.se an electronic copy of: CV, motivation letter and one-page summary of your research interests.

REGISTRATION DEADLINE: May 14, 2013
On May 2 you will be notified by e-mail about your acceptance. Registration fee: 3,500SEK (≈ 551 USD). This includes attendance to the conference, conference material, accommodation, coffee breaks, lunches and dinners, and social activities.

POSTER ABSTRACT SUBMISSION DEADLINE: May 30, 2013

Further information is available at: http://ki.se/act